CD46 targeted (212)Pb alpha particle radioimmunotherapy for prostate cancer treatment

We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an internalizing human monoclonal antibody YS5 th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Huang, Tao, Hua, Jun, Wang, Qiong, Su, Yang, Chen, Ping, Bidlingmaier, Scott, Li, Allan, Xie, Zhongqiu, Bidkar, Anil P., Shen, Sui, Shi, Weibin, Seo, Youngho, Flavell, Robert R., Gioeli, Daniel, Dreicer, Robert, Li, Hui, Liu, Bin, He, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007843/
https://www.ncbi.nlm.nih.gov/pubmed/36906664
http://dx.doi.org/10.1186/s13046-023-02636-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007843/
https://www.ncbi.nlm.nih.gov/pubmed/36906664
http://dx.doi.org/10.1186/s13046-023-02636-x

Ejemplares similares